+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Dialysis Membranes Inhibit in vitro Release of Beta-2-Microglobulin from Human Lymphocytes

      , ,


      S. Karger AG

      Haemodialysis, β2-Microglobulin, Lymphocytes

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          In the present study the effect of different dialysis membrane materials on in vitro β<sub>2</sub>-microglobulin (β<sub>2</sub>M) release by human lymphocytes was investigated. Lymphocytes were isolated from 11 long-term haemodialysis patients and 9 healthy controls. Cells were cultured either on flat sheet membranes made from Cuprophan, Hemophan and polyacrylonitrile or on polystyrol. β<sub>2</sub>M concentrations in the supernatant were measured at 3 and 7 days of culture, respectively. The β<sub>2</sub>M release from lymphocytes obtained from uraemic patients was almost identical with the release from healthy subjects. In the presence of all three membranes the release of β<sub>2</sub>M was less of what was produced on polystyrol. This held true for lymphocytes isolated from both healthy and uraemic subjects. As for the three membrane materials, the release of β<sub>2</sub>M into the supernatants was statistically not different when the adsorptive capacity of polyacrylonitrile was taken into account. However, there was a tendency for Cuprophan to exert the strongest inhibition, while Hemophan and polyacrylonitrile reduced β<sub>2</sub>M release to a lesser degree. Based on these data it seems that the increase in serum β<sub>2</sub>M which has been observed during dialysis with Cuprophan membranes is not caused by direct interaction of lymphocytes with Cuprophan membranes.

          Related collections

          Author and article information

          S. Karger AG
          10 December 2008
          : 56
          : 3
          : 267-270
          Department of Internal Medicine, Division of Nephrology, University of Würzburg, FRG
          186152 Nephron 1990;56:267–270
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 4
          Original Paper

          Cardiovascular Medicine, Nephrology

          Lymphocytes, Haemodialysis, β2-Microglobulin


          Comment on this article